BS PHARM KOREA Expands Aesthetic Portfolio with Organoid and Peptide Technologies
South Korean firm BS PHARM KOREA is adding laboratory-grown organoid ECM and multi-peptide formulations to its professional aesthetic product line.
BS PHARM KOREA has expanded its range of professional aesthetic products, introducing new formulations based on laboratory-grown organoid extracellular matrix (ECM) and multi-peptide technologies. The announcement follows the company's October 2026 launch of its EVErECM and EVE ARI product lines.
The inclusion of organoid-based ECM reflects a broader trend in the South Korean skincare industry toward integrating biotechnology into clinical dermatological applications. By moving beyond traditional formulations, the company aims to offer ingredients that interact with cellular regeneration processes.
This development marks a continued effort by the firm to capture a larger share of the professional-grade aesthetic market. The new products are intended for use by skincare professionals, focusing on the intersection of biological research and clinical skincare routines.